GlassScriptPhysician profile
Dean N Cassimatis
NPI 1821097742
$20,507.39
in general payments reported to CMS, 2019-2025
40 companies · $1,939 in 2025
The $1,939 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,930 · 2020: $2,536 · 2021: $3,854 · 2022: $3,905 · 2023: $2,388 · 2024: $2,956 · 2025: $1,939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,185 · Education: $97.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,184.74 |
| Education | $97.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $4,194.42 | 2019-2025 | Trulance, Xifaxan, Plenvu |
| Abbvie INC. | $3,446.20 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $2,827.83 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Pfizer INC. | $1,248.29 | 2019-2025 | |
| Gilead Sciences, INC. | $886.01 | 2019-2025 | Epclusa |
| Takeda Pharmaceuticals U.S.A., INC. | $759.93 | 2019-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $730.04 | 2022-2025 | |
| Celgene Corporation | $662.53 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $547.46 | 2022-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $540.54 | 2020-2023 | |
| Redhill Biopharma INC. | $449.54 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $441.26 | 2019-2025 | Rebyota |
| Janssen Scientific Affairs, LLC | $388.87 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $272.27 | 2024-2025 | Zenpep, Vowst |
| Intercept Pharmaceuticals, INC. | $267.79 | 2022-2025 | Ocaliva |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $259.76 | 2020-2025 | Sucraid, Sucraid |
| Cumberland Pharmaceuticals, INC. | $253.84 | 2020-2023 | Kristalose |
| Braintree Laboratories, INC. | $242.39 | 2019-2023 | Sutab |
| Ardelyx, INC. | $238.20 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $227.84 | 2019-2024 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $204.94 | 2021-2022 | |
| Allergan, INC. | $200.57 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $200.44 | 2020-2023 | Dificid |
| Ucb, INC. | $136.92 | 2019 | |
| Endo Pharmaceuticals INC. | $99.29 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $97.22 | 2024-2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $87.20 | 2024-2025 | Voquezna |
| Concordia Pharmaceuticals INC. | $77.53 | 2019 | |
| Romark Laboratories, Lc | $69.50 | 2019 | |
| Exact Sciences Corporation | $66.42 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.12 | 2023 | Cyltezo |
| Avanir Pharmaceuticals, INC. | $51.58 | 2019-2022 | |
| Novo Nordisk INC | $48.68 | 2019-2025 | Wegovy |
| Alfasigma USA, INC. | $39.93 | 2020 | |
| Capsovision, INC. | $36.30 | 2023-2024 | Capsocam Plus |
| Fresenius Kabi USA, LLC | $34.45 | 2023 | Idacio |
| Lilly USA, LLC | $32.91 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $30.32 | 2024 | Vegzelma |
| Organon LLC | $25.13 | 2023 | Renflexis, Hadlima |
| Ultragenyx Pharmaceutical INC. | $19.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Cassimatis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.